Pharmacological treatments, particularly the advent of novel agents such as GLP-1 RAs, have expanded therapeutic options for patients unable or unwilling to undergo surgery, as well as those with mild to moderate obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.